NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026 - PubMed
7 hours ago
- #Richter transformation
- #BTK inhibitors
- #CLL/SLL
- BTK inhibitors (BTKis) and BCL2 inhibitor (BCL2i)-containing regimens improve survival in CLL/SLL patients.
- Time-limited BCL2i regimens achieve higher undetectable measurable residual disease (uMRD) rates than BTKi monotherapy or chemoimmunotherapy (CIT).
- Newer treatments for relapsed/refractory disease include pirtobrutinib (noncovalent BTKi) and lisocabtagene maraleucel (CAR T-cell therapy).
- Richter transformation (CLL/SLL to diffuse large B-cell lymphoma) has a poor prognosis.
- Molecular analysis helps determine clonal relationship between CLL/SLL and transformed lymphoma for treatment selection.
- NCCN Guidelines provide updates on CLL/SLL and Richter transformation treatment.